Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immune-based mutation classification enables neoantigen prioritization and immune feature discovery in cancer immunotherapy.

Oncoimmunology - 15 Jan 2021

Bai Peng, Li Yongzheng, Zhou Qiuping, Xia Jiaqi, Wei Peng-Cheng, Deng Hexiang, Wu Min, Chan Sanny K, Kappler John W, Zhou Yu, Tran Eric, Marrack Philippa, Yin Lei

Abstract excerpt

Genetic mutations lead to the production of mutated proteins from which peptides are presented to T cells as cancer neoantigens. Evidence suggests that T cells that target neoantigens are the main mediators of effective cancer immunotherapies. Although algorithms have been used to predict neoantigens, only a minority are immunogenic. The factors that influence neoantigen immunogenicity are not completely...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, Neoplasm
Share to Immunotherapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunotherapy and Immune Responses

Share to Monoclonal and Polyclonal Antibodies Research

Share to Mutation

Share to Neoplasms

Share to T-Lymphocytes

Share to vaccines and immunoinformatics approaches

Source

Open in PubMed Open full text

Identifiers

PMID: 33537173
DOI: 10.1080/2162402X.2020.1868130
PMCID: PMC7833777

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immune-based mutation classification enables neoantigen prioritization and immune feature discovery in cancer immunotherapy.PMID 33537173Read ↗

Immune-based mutation classification enables neoantigen prioritization and immune feature discovery in cancer immunotherapySemantic proximity Read ↗

Neoantigen prioritization based on antigen processing and presentation.Semantic proximity Read ↗

Advances and challenges in neoantigen prediction for cancer immunotherapySemantic proximity Read ↗

Computational methods and data resources for predicting tumor neoantigensSemantic proximity Read ↗

Best practices for bioinformatic characterization of neoantigens for clinical utility.Semantic proximity Read ↗

Characterizing neoantigens for personalized cancer immunotherapy.Semantic proximity Read ↗

Mutation position is an important determinant for predicting cancer neoantigens.Semantic proximity Read ↗

Computational cancer neoantigen prediction: current status and recent advancesSemantic proximity Read ↗

Computational prediction of MHC anchor locations guide neoantigen identification and prioritizationSemantic proximity Read ↗

Computational prediction of MHC anchor locations guides neoantigen identification and prioritization.Semantic proximity Read ↗

Strategies for neoantigen screening and immunogenicity validation in cancer immunotherapy (Review)Semantic proximity Read ↗

Utilizing immunogenomic approaches to prioritize targetable neoantigens for personalized cancer immunotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.